Kyle Juraschka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kyle Juraschka has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
- Michael D. Taylor
Texas Children’s Hospital, Baylor College of Medicine , Houston, Texas
16 shared publications - Sachin A. Kumar
The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada
14 shared publications - Hiromichi Suzuki
Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
13 shared publications - Pasqualino De Antonellis
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy
13 shared publications - Olivier Saulnier
The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada
12 shared publications - Alexandra Rasnitsyn
The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada
11 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 3 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 3 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy